8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 23, 2026·SEC
Nektar Therapeutics(NKTR)Earnings, Financials & Key Ratios
NKTR•NASDAQ
Price updated Jun 19, 2026
AboutNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.Show more
- Revenue$55M-43.9%
- EBITDA-$130M-28.7%
- Net Income-$164M-37.9%
- EPS (Diluted)-9.73-12.1%
- Gross Margin100%+45.3%
- EBITDA Margin-234.91%-129.4%
- Operating Margin-236.77%-121.5%
- Net Margin-297.07%-145.8%
- ROE-217.94%-75.6%
NKTR Key Insights
Nektar Therapeutics (NKTR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 18.1%
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 18.4% over 5 years
- ✗Shares diluted 23.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 11.5x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NKTR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NKTR Price & Volume
Nektar Therapeutics (NKTR) stock price & volume — 10-year historical chart
Loading chart...
NKTR Growth Metrics
Nektar Therapeutics (NKTR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-13.32%
5 Years-18.43%
3 Years-15.66%
TTM-36.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-18.83%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM11.65%
Return on Capital
10 Years-21.51%
5 Years-36.85%
3 Years-39.74%
Last Year-55.73%
NKTR Recent Earnings
Nektar Therapeutics (NKTR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.82-4.6%
$1.74
Rev
$11M+1.6%
$11M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$1.78+35.5%
$2.76
Rev
$22M+114.0%
$10M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.85+35.1%
$2.85
Rev
$12M+12.9%
$10M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$2.95+5.8%
$3.13
Rev
$11M+18.7%
$9M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.82vs $1.74-4.6% | $11Mvs $11M+1.6% |
| Q2 2026 | Mar 12, 2026 | $1.78vs $2.76+35.5% | $22Mvs $10M+114.0% |
| Q4 2025 | Nov 6, 2025 | $1.85vs $2.85+35.1% | $12Mvs $10M+12.9% |
| Q3 2025 | Aug 7, 2025 | $2.95vs $3.13+5.8% | $11Mvs $9M+18.7% |
Based on last 12 quarters of dataView full earnings history →
NKTR Peer Comparison
Nektar Therapeutics (NKTR) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 INCY | 19.62B | 98.22 | 15.32 | 21.22% | 26.71% | 29.31% | 0.01 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 |
Compare NKTR vs Peers
Nektar Therapeutics (NKTR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NKTR Income Statement
Nektar Therapeutics (NKTR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 307.71M | 1.19B | 114.62M | 152.91M | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M | 55.63M |
Revenue Growth % | 86% | 287.81% | -90.4% | 33.41% | -33.36% | -9.67% | -2.1% | 9.22% | -43.89% | -36.24% |
Cost of Goods Sold | 30.55M | 24.41M | 21.37M | 19.48M | 24.9M | 21.64M | 36.64M | 30.69M | 0 | 347K |
COGS % of Revenue | 9.93% | 2.05% | 18.65% | 12.74% | 24.43% | 23.5% | 40.66% | 31.18% | - | - |
Gross Profit | 277.16M▲ 0% | 1.17B▲ 321.7% | 93.24M▼ 92.0% | 133.44M▲ 43.1% | 77.01M▼ 42.3% | 70.42M▼ 8.6% | 53.48M▼ 24.1% | 67.74M▲ 26.7% | 55.23M▼ 18.5% | 55.29M▲ 0% |
Gross Margin % | 90.07% | 97.95% | 81.35% | 87.26% | 75.57% | 76.5% | 59.34% | 68.82% | 100% | 99.38% |
Gross Profit Growth % | 104.97% | 321.74% | -92.02% | 43.11% | -42.29% | -8.56% | -24.06% | 26.67% | -18.47% | - |
Operating Expenses | 320.82M | 480.98M | 533.28M | 513.36M | 523.11M | 310.66M | 190.9M | 172.94M | 186M | 180.4M |
OpEx % of Revenue | 104.26% | 40.31% | 465.27% | 335.72% | 513.32% | 337.47% | 211.83% | 175.7% | 336.77% | - |
Selling, General & Admin | 52.36M | 81.44M | 98.71M | 104.68M | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M | 57.62M |
SG&A % of Revenue | 17.02% | 6.82% | 86.12% | 68.46% | 120.55% | 100.3% | 85.9% | 77.98% | 124.34% | - |
Research & Development | 268.46M | 399.54M | 434.57M | 408.68M | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M | 122.53M |
R&D % of Revenue | 87.24% | 33.48% | 379.15% | 267.26% | 392.78% | 237.17% | 126.68% | 122.84% | 212.43% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -676K | -24.72M | 0 | 251K |
Operating Income | -59.64M▲ 0% | 687.93M▲ 1253.4% | -440.04M▼ 164.0% | -379.92M▲ 13.7% | -446.1M▼ 17.4% | -240.24M▲ 46.1% | -137.43M▲ 42.8% | -105.2M▲ 23.5% | -130.77M▼ 24.3% | -125.11M▲ 0% |
Operating Margin % | -19.38% | 57.65% | -383.92% | -248.45% | -437.76% | -260.97% | -152.49% | -106.88% | -236.77% | -224.88% |
Operating Income Growth % | 47.15% | 1253.44% | -163.96% | 13.66% | -17.42% | 46.15% | 42.8% | 23.45% | -24.31% | - |
EBITDA | -47.04M | 696.73M | -429.04M | -367.42M | -431.96M | -228.04M | -129.61M | -100.81M | -129.74M | -124.36M |
EBITDA Margin % | -15.29% | 58.39% | -374.32% | -240.28% | -423.87% | -247.72% | -143.82% | -102.42% | -234.91% | -223.53% |
EBITDA Growth % | 52.8% | 1581.09% | -161.58% | 14.36% | -17.56% | 47.21% | 43.16% | 22.22% | -28.71% | -11.94% |
D&A (Non-Cash Add-back) | 12.6M | 8.8M | 11M | 12.5M | 14.15M | 12.2M | 7.82M | 4.39M | 1.03M | 751K |
EBIT | -55.12M | 725.5M | -393.7M | -406.83M | -475.97M | -336.07M | -250.92M | -91.09M | -130.77M | -120.86M |
Net Interest Income | -36.43M | -5.21M | -19K | -18.84M | -44.58M | -22.13M | -6.33M | -13.61M | -15.75M | -17.35M |
Interest Income | 4.52M | 37.57M | 46.34M | 18.28M | 2.73M | 6.78M | 19.01M | 14.5M | 10.44M | 11.81M |
Interest Expense | 40.95M | 42.78M | 46.35M | 37.12M | 47.31M | 28.91M | 25.33M | 28.11M | 26.18M | 29.15M |
Other Income/Expense | -36.43M | -5.21M | -19K | -64.03M | -77.18M | -124.75M | -138.83M | -14M | -33.44M | -33.11M |
Pretax Income | -96.08M▲ 0% | 682.73M▲ 810.6% | -440.05M▼ 164.5% | -443.95M▼ 0.9% | -523.28M▼ 17.9% | -364.98M▲ 30.3% | -276.26M▲ 24.3% | -119.2M▲ 56.9% | -164.21M▼ 37.8% | -158.22M▲ 0% |
Pretax Margin % | -31.22% | 57.21% | -383.93% | -290.32% | -513.49% | -396.48% | -306.54% | -121.1% | -297.32% | -284.41% |
Income Tax | 616K | 1.41M | 613K | 493K | 557K | 3.21M | -200K | -239K | -138K | -126K |
Effective Tax Rate % | -0.64% | 0.21% | -0.14% | -0.11% | -0.11% | -0.88% | 0.07% | 0.2% | 0.08% | 0.08% |
Net Income | -96.69M▲ 0% | 681.31M▲ 804.6% | -440.67M▼ 164.7% | -444.44M▼ 0.9% | -523.84M▼ 17.9% | -368.2M▲ 29.7% | -276.06M▲ 25.0% | -118.96M▲ 56.9% | -164.08M▼ 37.9% | -158.1M▲ 0% |
Net Margin % | -31.42% | 57.09% | -384.47% | -290.65% | -514.03% | -399.98% | -306.31% | -120.86% | -297.07% | -284.18% |
Net Income Growth % | 37.02% | 804.62% | -164.68% | -0.86% | -17.86% | 29.71% | 25.03% | 56.91% | -37.92% | -18.83% |
Net Income (Continuing) | -96.69M | 681.31M | -440.67M | -444.44M | -523.84M | -368.2M | -276.06M | -118.96M | -164.08M | -158.1M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -9.30▲ 0% | 56.70▲ 709.7% | -37.80▼ 166.7% | -37.33▲ 1.2% | -42.90▼ 14.9% | -29.51▲ 31.2% | -21.79▲ 26.2% | -8.68▲ 60.2% | -9.73▼ 12.1% | -6.39▲ 0% |
EPS Growth % | 43.64% | 709.68% | -166.67% | 1.24% | -14.92% | 31.21% | 26.16% | 60.17% | -12.1% | 11.65% |
EPS (Basic) | -9.30 | 56.70 | -37.80 | -37.33 | -42.90 | -29.51 | -21.79 | -8.68 | -9.73 | - |
Diluted Shares Outstanding | 10.4M | 12.01M | 11.67M | 11.91M | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M | 24.74M |
Basic Shares Outstanding | 10.4M | 12.01M | 11.67M | 11.91M | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M | 24.74M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NKTR Balance Sheet
Nektar Therapeutics (NKTR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 326.82M | 1.44B | 1.42B | 1.14B | 795.58M | 545.97M | 330.7M | 261.29M | 266.27M | 589.04M |
Cash & Short-Term Investments | 296.13M | 1.34B | 1.32B | 1.06B | 733.96M | 504.98M | 303.62M | 255.23M | 245.75M | 568.6M |
Cash Only | 4.76M | 194.91M | 96.36M | 198.96M | 25.22M | 88.23M | 35.28M | 44.25M | 15.12M | 131.87M |
Short-Term Investments | 291.37M | 1.14B | 1.23B | 862.94M | 708.74M | 416.75M | 268.34M | 210.97M | 230.64M | 436.74M |
Accounts Receivable | 5.01M | 43.21M | 36.8M | 38.89M | 22.49M | 8.4M | 2.25M | 1.61M | 1.78M | 3.6M |
Days Sales Outstanding | 5.95 | 13.22 | 117.2 | 92.83 | 80.56 | 33.32 | 9.12 | 5.97 | 11.76 | 13.15 |
Inventory | 10.73M | 11.38M | 12.66M | 15.29M | 15.8M | 19.2M | 16.1M | 0 | 0 | 0 |
Days Inventory Outstanding | 128.16 | 170.16 | 216.28 | 286.57 | 231.65 | 323.95 | 160.38 | - | - | - |
Other Current Assets | 14.35M | 21.29M | 15.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 182.05M | 712.49M | 555.81M | 400.76M | 321.61M | 164.63M | 67.33M | 42.56M | 14.14M | 174.23M |
Property, Plant & Equipment | 47.46M | 48.85M | 199.84M | 186.14M | 177.53M | 85.89M | 36.86M | 11.82M | 5M | 4.72M |
Fixed Asset Turnover | 6.48x | 24.43x | 0.57x | 0.82x | 0.57x | 1.07x | 2.44x | 8.32x | 11.04x | 7.35x |
Goodwill | 76.5M | 76.5M | 76.5M | 76.5M | 76.5M | 76.5M | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 57.09M | 582.89M | 279.12M | 136.66M | 64.83M | 0 | 25.82M | 26.09M | 0 | 178.43M |
Other Non-Current Assets | 994K | 4.24M | 344K | 1.46M | 2.74M | 2.25M | 4.64M | 4.65M | 9.14M | 4.78M |
Total Assets | 508.87M▲ 0% | 2.15B▲ 322.5% | 1.98B▼ 8.0% | 1.54B▼ 22.2% | 1.12B▼ 27.4% | 710.6M▼ 36.4% | 398.03M▼ 44.0% | 303.85M▼ 23.7% | 280.41M▼ 7.7% | 763.27M▲ 0% |
Asset Turnover | 0.60x | 0.55x | 0.06x | 0.10x | 0.09x | 0.13x | 0.23x | 0.32x | 0.20x | 0.14x |
Asset Growth % | -10.55% | 322.54% | -8.04% | -22.18% | -27.4% | -36.39% | -43.99% | -23.66% | -7.72% | 148.45% |
Total Current Liabilities | 56.16M | 82M | 353.89M | 115.78M | 85.2M | 68.2M | 51.27M | 61.4M | 53.54M | 57.71M |
Accounts Payable | 4.78M | 5.85M | 19.23M | 22.14M | 9.75M | 12.98M | 9.85M | 11.56M | 10.77M | 10.03M |
Days Payables Outstanding | 57.14 | 87.53 | 328.46 | 414.89 | 142.89 | 218.98 | 98.09 | 137.5 | - | 13.32K |
Short-Term Debt | 0 | 0 | 252.89M | 0 | 0 | 0 | 0 | 0 | 20.5M | 22.53M |
Deferred Revenue (Current) | 18.95M | 13.89M | 5.52M | 91K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 24.17M | 52.32M | 11.47M | 14.44M | 15.73M | 9.58M | 5.55M | 5.55M | 22.27M | 20.14M |
Current Ratio | 5.82x | 17.53x | 4.02x | 9.83x | 9.34x | 8.00x | 6.45x | 4.26x | 4.97x | 10.21x |
Quick Ratio | 5.63x | 17.39x | 3.98x | 9.70x | 9.15x | 7.72x | 6.14x | 4.26x | 4.97x | 10.21x |
Cash Conversion Cycle | 76.97 | 95.86 | 5.02 | -35.49 | 169.31 | 138.29 | 71.41 | - | - | -13.3K |
Total Non-Current Liabilities | 364.88M | 350.6M | 218.07M | 345.69M | 352.48M | 275.76M | 215.78M | 181.71M | 137.04M | 129.35M |
Long-Term Debt | 245.21M | 246.95M | 0 | 0 | 0 | 0 | 0 | 0 | 63.16M | 60.27M |
Capital Lease Obligations | 0 | 0 | 142.73M | 136.37M | 125.74M | 112.83M | 98.52M | 82.7M | 65.26M | 269.76M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 100.65M | 92.9M | 72.79M | 206.86M | 226.75M | 162.93M | 117.26M | 99.02M | 8.63M | 8.45M |
Total Liabilities | 421.04M | 432.6M | 571.97M | 461.47M | 437.68M | 343.96M | 267.05M | 243.11M | 190.57M | 187.06M |
Total Debt | 245.21M | 246.95M | 408.14M | 150.29M | 143.18M | 131.5M | 117.78M | 102.56M | 148.91M | 143.43M |
Net Debt | 240.44M | 52.05M | 311.77M | -48.67M | 117.96M | 43.27M | 82.5M | 58.31M | 133.79M | 11.56M |
Debt / Equity | 2.79x | 0.14x | 0.29x | 0.14x | 0.21x | 0.36x | 0.90x | 1.69x | 1.66x | 0.25x |
Debt / EBITDA | - | 0.35x | - | - | - | - | - | - | - | -1.15x |
Net Debt / EBITDA | - | 0.07x | - | - | - | - | - | - | - | -0.09x |
Interest Coverage | -1.35x | 16.96x | -8.49x | -10.96x | -10.06x | -11.62x | -9.90x | -3.24x | -4.99x | -4.15x |
Total Equity | 87.83M▲ 0% | 1.72B▲ 1855.6% | 1.41B▼ 18.2% | 1.08B▼ 23.3% | 679.51M▼ 36.9% | 366.64M▼ 46.0% | 130.99M▼ 64.3% | 60.74M▼ 53.6% | 89.83M▲ 47.9% | 576.22M▲ 0% |
Equity Growth % | -0.34% | 1855.61% | -18.18% | -23.35% | -36.92% | -46.04% | -64.27% | -53.63% | 47.9% | 4085.9% |
Book Value per Share | 8.45 | 143.04 | 120.47 | 90.49 | 55.61 | 29.39 | 10.34 | 4.43 | 5.32 | 23.29 |
Total Shareholders' Equity | 87.83M | 1.72B | 1.41B | 1.08B | 679.51M | 366.64M | 130.99M | 60.74M | 89.83M | 576.22M |
Common Stock | 15K | 17K | 17K | 18K | 19K | 19K | 19K | 19K | 2K | 3K |
Retained Earnings | -2.12B | -1.42B | -1.86B | -2.31B | -2.83B | -3.2B | -3.48B | -3.6B | -3.76B | -3.81B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3M | 0 | 0 |
Accumulated OCI | -2.11M | -6.32M | -1M | -2.29M | -4.16M | -6.91M | 80K | 61K | 17K | -1.03M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NKTR Cash Flow Statement
Nektar Therapeutics (NKTR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -80.41M | 718.21M | -328.68M | -313.29M | -412.66M | -304.01M | -192.61M | -175.71M | -208.51M | -203.76M |
Operating CF Margin % | -26.13% | 60.19% | -286.76% | -204.88% | -404.94% | -330.25% | -213.72% | -178.52% | -377.52% | - |
Operating CF Growth % | 31.28% | 993.15% | -145.76% | 4.68% | -31.72% | 26.33% | 36.64% | 8.77% | -18.67% | -63.26% |
Net Income | -96.69M | 681.31M | -440.67M | -444.44M | -523.84M | -368.2M | -276.06M | -118.96M | -164.08M | -158.1M |
Depreciation & Amortization | 14.74M | 10.87M | 13.16M | 14.18M | 14.15M | 13.03M | 7.82M | 4.39M | -4.49M | -682K |
Stock-Based Compensation | 36.62M | 88.1M | 99.8M | 94.26M | 94.67M | 57.32M | 33.39M | 21.61M | 12.65M | 8.75M |
Deferred Taxes | 15.08M | 0 | 0 | 20.35M | 8.02M | 2.71M | -140K | 0 | 0 | 0 |
Other Non-Cash Items | -12.54M | -23.06M | -22.65M | -14.35M | 17.41M | -9.36M | 62.19M | -76.51M | -15.58M | -16.79M |
Working Capital Changes | -37.62M | -39.01M | 21.69M | 16.71M | -23.08M | 492K | -19.8M | -6.24M | -37.02M | -36.94M |
Change in Receivables | 10.66M | -25.5M | 6.41M | 1.91M | 12.4M | 16.51M | 4.78M | -3.04M | 0 | 0 |
Change in Inventory | 383K | -655K | -1.28M | -2.63M | -509K | -3.4M | 699K | 497K | 0 | 0 |
Change in Payables | 2.07M | 971K | 12.97M | 2.38M | -11.69M | 3.1M | -2.88M | 2.67M | -625K | -7.97M |
Cash from Investing | -28.81M | -1.38B | 206.89M | 496.21M | 202.78M | 365.83M | 139.56M | 142.57M | -1.2M | -395.68M |
Capital Expenditures | -9.68M | -14.24M | -26.29M | -7.26M | -14.99M | -5.68M | -865K | -1.47M | -171K | -187K |
CapEx % of Revenue | 3.14% | 1.19% | 22.93% | 4.75% | 14.71% | 6.17% | 0.96% | 1.49% | 0.31% | 0.34% |
Acquisitions | 0 | 2.63M | 0 | -503.47M | -217.77M | 13.2M | 0 | 65.39M | -697K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -19.13M | 2.63M | 0 | 503.47M | 217.77M | 0 | 1.25M | 0 | 0 | 0 |
Cash from Financing | 54.39M | 851.97M | 23.36M | -80.35M | 36.24M | 1.51M | 30K | 42.12M | 180.57M | 710.11M |
Debt Issued (Net) | -5.13M | 0 | 0 | -103.75M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 790.23M | 0 | 23.4M | 33.24M | 758K | 30K | -3M | 180.57M | 710.11M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3M | 0 | 0 |
Other Financing | 59.52M | 61.73M | 23.36M | 0 | 3M | 750K | 0 | 45.12M | 0 | 0 |
Net Change in Cash | -54.88M▲ 0% | 190.14M▲ 446.5% | -98.54M▼ 151.8% | 102.59M▲ 204.1% | -173.74M▼ 269.3% | 63.01M▲ 136.3% | -52.95M▼ 184.0% | 8.97M▲ 116.9% | -29.14M▼ 424.6% | 129.61M▲ 0% |
Free Cash Flow | -90.09M▲ 0% | 703.98M▲ 881.4% | -354.97M▼ 150.4% | -320.55M▲ 9.7% | -427.65M▼ 33.4% | -309.68M▲ 27.6% | -193.47M▲ 37.5% | -177.18M▲ 8.4% | -208.68M▼ 17.8% | -203.94M▲ 0% |
FCF Margin % | -29.28% | 58.99% | -309.7% | -209.62% | -419.65% | -336.41% | -214.68% | -180.01% | -377.83% | -366.59% |
FCF Growth % | 27% | 881.41% | -150.42% | 9.7% | -33.41% | 27.58% | 37.53% | 8.42% | -17.78% | -14.45% |
FCF per Share | -8.67 | 58.63 | -30.43 | -26.92 | -35.00 | -24.82 | -15.27 | -12.92 | -12.37 | -8.24 |
FCF Conversion (FCF/Net Income) | 0.83x | 1.05x | 0.75x | 0.70x | 0.79x | 0.83x | 0.70x | 1.48x | 1.27x | 1.29x |
Interest Paid | 20.12M | 19.47M | 19.2M | 9.74M | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 556K | 618K | 555K | 539K | 325K | 272K | 2.66M | 76K | 0 | 0 |
NKTR Key Ratios
Nektar Therapeutics (NKTR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -109.91% | 75.47% | -28.22% | -35.8% | -59.64% | -70.39% | -110.95% | -124.1% | -217.94% | -87% |
Return on Invested Capital (ROIC) | -14.78% | 49.19% | -18.93% | -20.75% | -36.64% | -29.85% | -33.07% | -47.45% | -57.24% | -38.44% |
Gross Margin | 90.07% | 97.95% | 81.35% | 87.26% | 75.57% | 76.5% | 59.34% | 68.82% | 100% | 99.38% |
Net Margin | -31.42% | 57.09% | -384.47% | -290.65% | -514.03% | -399.98% | -306.31% | -120.86% | -297.07% | -284.18% |
Debt / Equity | 2.79x | 0.14x | 0.29x | 0.14x | 0.21x | 0.36x | 0.90x | 1.69x | 1.66x | 0.25x |
Interest Coverage | -1.35x | 16.96x | -8.49x | -10.96x | -10.06x | -11.62x | -9.90x | -3.24x | -4.99x | -4.15x |
FCF Conversion | 0.83x | 1.05x | 0.75x | 0.70x | 0.79x | 0.83x | 0.70x | 1.48x | 1.27x | 1.29x |
Revenue Growth | 86% | 287.81% | -90.4% | 33.41% | -33.36% | -9.67% | -2.1% | 9.22% | -43.89% | -36.24% |
Related:NKTR Dividend History·NKTR Revenue History·NKTR Price History·NKTR P/E History·NKTR Financial Ratios·NKTR Institutional Holders
NKTR SEC Filings & Documents
Nektar Therapeutics (NKTR) SEC filings — annual & quarterly reports (10-K, 10-Q)
NKTR Frequently Asked Questions
Nektar Therapeutics (NKTR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nektar Therapeutics (NKTR) reported $55.6M in revenue for fiscal year 2025. This represents a 706% increase from $6.9M in 1996.
Nektar Therapeutics (NKTR) saw revenue decline by 43.9% over the past year.
Nektar Therapeutics (NKTR) reported a net loss of $158.1M for fiscal year 2025.
Dividend & Returns
Nektar Therapeutics (NKTR) has a return on equity (ROE) of -217.9%. Negative ROE indicates the company is unprofitable.
Nektar Therapeutics (NKTR) had negative free cash flow of $203.9M in fiscal year 2025, likely due to heavy capital investments.